MedTrace Logo

Effect of Fasting Free Fatty Acids and Fasting Glucose on 1st and 2nd Phase Insulin Secretion

NCT03998709 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2022-09-09

No results posted yet for this study

Summary

Researchers are trying to determine how changes in fasting glucose and free fatty acids (products released from fat) affect insulin secretion.

Conditions

  • Healthy

Interventions

DRUG

Somatostatin

Somatostatin will be used to inhibit endogenous insulin secretion on either study day in both arms of the study

OTHER

Dextrose

intravenous glucose will be used to raise fasting glucose in people with NFG / NGT

DRUG

Insulin

insulin will be used to lower fasting FFA and glucose in people with IFG / IGT

OTHER

Intralipid

intravenous intralipid (Fat Emulsion) will be used to raise fasting FFA in people with NFG / NGT

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Mayo Clinic

    lead OTHER

Principal Investigators

  • Adrian Vella, MD · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2021-12-31
Completion
2022-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03998709 on ClinicalTrials.gov